Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S, Vyas D. MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol 2015; 21(27): 8284-8292 [PMID: 26217080 DOI: 10.3748/wjg.v21.i27.8284]
Corresponding Author of This Article
Dinesh Vyas, MD, MS, FICS, Department of Surgery, College of Human Medicine, Michigan State University, 1200 East Michigan Avenue, Suite 655, MI 48912, United States. dinesh.vyas@hc.msu.edu
Research Domain of This Article
Cell Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Michael Hollis, Lakshmi Shankar Chaturvedi, Sahil Gambhir, Dinesh Vyas, Department of Surgery, College of Human Medicine, Michigan State University, East Lansing, MI 48912, United States
Kavitha Nair, Department of Medicine, Emory University, Atlanta, GA 30322, United States
Arpita Vyas, Pediatrics, College of Human Medicine, Michigan State University, East Lansing, MI 49503, United States
Author contributions: Hollis M and Vyas A contributed equally to this work; they designed research, analyzed data, and wrote the paper; Nair K and Gambhir S contributed in research; Vyas D contributed in data and conceptualization; all authors finally approved the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dinesh Vyas, MD, MS, FICS, Department of Surgery, College of Human Medicine, Michigan State University, 1200 East Michigan Avenue, Suite 655, MI 48912, United States. dinesh.vyas@hc.msu.edu
Telephone: +1-517-2672491 Fax: +1-517-2672488
Received: January 20, 2015 Peer-review started: January 20, 2015 First decision: March 10, 2015 Revised: March 24, 2015 Accepted: May 27, 2015 Article in press: May 27, 2015 Published online: July 21, 2015 Processing time: 183 Days and 10.2 Hours
Abstract
Over the past decade, research has shown that aberrant expression of microRNA (miRNA) is involved in colorectal cancer development and progression. MicroRNAs are small sequences of non-coding RNA that regulate expression of genes involved in important cellular functions, such as cell differentiation, multiplication, and apoptosis. A specific miRNA may display the effects of a tumor suppressor or oncogene. Altered miRNA expression is found in colorectal cancer (CRC) and patterns of miRNA expression correlate with CRC detection and outcome. Studies also have examined the use of circulating serum miRNA and fecal miRNA expression as non-invasive markers for early detection. Here, we review recent evidence demonstrating the potential role of miRNA in CRC and the implications of its use in the diagnosis, prognosis, and management of CRC.
Core tip: Specific microRNA (miRNA) have potential to display the effects of a tumor suppressor or oncogene. Altered miRNA expression is found in colon cancer and patterns of miRNA expression correlate with its detection and outcome.
